MA49255A - Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa - Google Patents

Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa

Info

Publication number
MA49255A
MA49255A MA049255A MA49255A MA49255A MA 49255 A MA49255 A MA 49255A MA 049255 A MA049255 A MA 049255A MA 49255 A MA49255 A MA 49255A MA 49255 A MA49255 A MA 49255A
Authority
MA
Morocco
Prior art keywords
hsa
antibody format
heterodimeric antibody
specific heterodimeric
format targeting
Prior art date
Application number
MA049255A
Other languages
English (en)
Inventor
Tea Gunde
Christian Hess
Sebastian Meyer
Alexandre Simonin
David Urech
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MA49255A publication Critical patent/MA49255A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA049255A 2017-06-05 2018-06-04 Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa MA49255A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762515293P 2017-06-05 2017-06-05

Publications (1)

Publication Number Publication Date
MA49255A true MA49255A (fr) 2020-04-15

Family

ID=60473421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049255A MA49255A (fr) 2017-06-05 2018-06-04 Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa

Country Status (11)

Country Link
US (1) US12098203B2 (fr)
EP (1) EP3635014B1 (fr)
JP (1) JP7549961B2 (fr)
KR (1) KR20200013230A (fr)
CN (1) CN110719918B (fr)
AU (1) AU2018280683A1 (fr)
CA (1) CA3065868C (fr)
ES (1) ES2967739T3 (fr)
MA (1) MA49255A (fr)
SG (1) SG11201911527QA (fr)
WO (1) WO2018224443A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634998A1 (fr) * 2017-06-05 2020-04-15 Numab Therapeutics AG Nouveaux anticorps anti-cd3
JP7130678B2 (ja) * 2017-06-05 2022-09-05 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｈｓａ抗体
EP3774907A1 (fr) 2018-04-13 2021-02-17 Sangamo Therapeutics France Récepteur antigénique chimérique spécifique pour récepteur de l'interleukine 23
EP3897851A2 (fr) * 2018-12-17 2021-10-27 Revitope Limited Recruteur de cellules immunitaires jumelles
WO2020157305A1 (fr) * 2019-01-31 2020-08-06 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
EP3808766A1 (fr) * 2019-10-15 2021-04-21 Sangamo Therapeutics France Récepteur d'antigène chimérique spécifique pour récepteur de l'interleukine 23
EP3915580A1 (fr) * 2020-05-29 2021-12-01 Numab Therapeutics AG Anticorps multi-spécifique
EP4288451A1 (fr) * 2021-02-02 2023-12-13 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour ror1 et cd3
CN117003872A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 含有突变轻链可变区骨架的单链抗体片段
WO2024135812A1 (fr) * 2022-12-23 2024-06-27 Chugai Seiyaku Kabushiki Kaisha Complexe polypeptidique dont l'activité de liaison à l'antigène varie en fonction de la concentration d'une protéine plasmatique

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
EP1293514B1 (fr) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimères d'anticorps Fv monocaténaires en tandem
EP2445936A1 (fr) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques facilement isolés avec un format d'immunoglobuline native
BR112014001573B8 (pt) * 2011-07-22 2022-11-08 Affimed Therapeutics Ag Molécula fv ao antígeno multivalente
CA2864177C (fr) 2012-03-01 2019-11-26 Amgen Research (Munich) Gmbh Anticorps bispecifiques a proteine fusionnee liant l'albumine presentantune demi-vie prolongee
KR20210097829A (ko) 2013-06-26 2021-08-09 누맙 세러퓨틱스 아게 신규한 항체 기본구조
WO2015058861A1 (fr) 2013-10-25 2015-04-30 Numab Ag Constructions bispécifiques et leur utilisation dans le traitement de diverses maladies
JP2017521998A (ja) * 2014-05-12 2017-08-10 ヌマブ アクチェンゲゼルシャフト 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法
EP3298041A1 (fr) 2015-05-18 2018-03-28 Numab Therapeutics AG Nouvelles méthodes de traitement sur la base de molécules multifonctionnelles
IL274151B (en) 2015-05-21 2022-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
AU2016278586B2 (en) 2015-06-15 2022-05-19 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format
EP3634998A1 (fr) * 2017-06-05 2020-04-15 Numab Therapeutics AG Nouveaux anticorps anti-cd3
JP7130678B2 (ja) * 2017-06-05 2022-09-05 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｈｓａ抗体
CN109651507B (zh) * 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体

Also Published As

Publication number Publication date
EP3635014A1 (fr) 2020-04-15
WO2018224443A1 (fr) 2018-12-13
EP3635014B1 (fr) 2023-09-27
US12098203B2 (en) 2024-09-24
KR20200013230A (ko) 2020-02-06
ES2967739T3 (es) 2024-05-03
CN110719918A (zh) 2020-01-21
US20200181263A1 (en) 2020-06-11
JP7549961B2 (ja) 2024-09-12
EP3635014C0 (fr) 2023-09-27
CA3065868A1 (fr) 2018-12-13
AU2018280683A1 (en) 2019-10-17
CA3065868C (fr) 2024-06-04
CN110719918B (zh) 2024-05-24
JP2020522267A (ja) 2020-07-30
SG11201911527QA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MA49255A (fr) Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
MA42530A (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
ZA201900059B (en) Anti-b7-h3 antibodies and antibody drug conjugates
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA43955A (fr) Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA41279A (fr) Anticorps hétérodimériques se liant aux antigènes cd3 et tumoraux
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA47468A (fr) Anticorps anti-ilt3 et conjugués anticorps-médicament
MA49846A (fr) Anticorps qui se lient à l'egfr et à cmet
MA51903A (fr) Formulations d'anticorps b7-h4
MA39708A (fr) Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain
MA55818A (fr) Anticorps et immunoconjugués de fr-alpha biparatopique
MA51417A (fr) Constructions d'anticorps bispécifiques dirigés contre muc17 et cd3
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
ZA202104518B (en) Cd3 antibody and pharmaceutical use thereof
MA51902A (fr) Schémas posologiques d'anticorps b7-h4
IL278926A (en) Antibodies specific to CD3 and their uses
MA49273A (fr) Anticorps anti-tmeff1 et conjugués anticorps-médicament
MA52021A (fr) Anticorps anti-lif et leurs formes galéniques
GB201815045D0 (en) Bispecific antibody targeting IL-1R1 and NLPR3